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LETTERS TO THE EDITOR
Did Contrast Nephropathy
in RAPPID Really Occur?
Ever since Tepel et al. (1) first reported that n-acetylcysteine
(NAC) was effective in preventing radiocontrast-induced nephrop-
athy (RCIN) in patients undergoing computed tomography, there
has been considerable debate regarding the ideal strategy to
prevent RCIN. Several studies have suggested that NAC may also
prevent RCIN in patients undergoing coronary angiography (2–4).
In contrast, others have suggested that neither NAC nor fenoldo-
pam offers additional protection against RCIN compared with
hydration therapy (5).
In the June 18, 2003, issue of the Journal, Baker et al. (6)
reported the results of the RAPPID study comparing intravenous
(IV) NAC to standard hydration therapy in patients undergoing
coronary angiography. Patients were randomized to either hydra-
tion therapy with saline or hydration plus IV NAC (150 mg/kg
immediately before contrast exposure followed by 50 mg/kg
over the following 4 h). The study was terminated following the
interim analysis after the first 80 patients had been randomized
(planned enrollment was 160 patients). The incidence of RCIN
was reduced by 72% in patients given IV NAC compared to
those receiving hydration alone (5% vs. 21%, p  0.045; relative
risk [RR] 0.28; 95% confidence interval [CI] 0.08 to 0.98). The
investigators concluded that IV NAC should be considered in
all patients at risk for RCIN when time constraints prevent oral
prophylaxis.
If one looks closely at the definition of RCIN (25% increase in
serum creatinine [SCr]) provided by Baker et al. (6) and the
absolute changes reported in SCr values at both 48 and 96 h, the
findings appear inconsistent. Although IV NAC dramatically
reduced the risk of RCIN, the mean changes in SCr in the IV
NAC group were 0.08 mg/dl and 0.06 mg/dl at 48 and 96 h,
respectively, compared with 0.06 mg/dl and 0.05 mg/dl for the
hydration-alone group at the same time periods. This corresponds
to between-group differences in SCr of 0.14 mg/dl and 0.11 mg/dl
at 48 and 96 h, considerably less than the 0.6-mg/dl difference
required to meet a priori power calculations. Because the study was
terminated due to changes in secondary outcomes yet failed to
show a difference in the primary outcome, the significance of these
findings is in question. Despite the dramatic reduction in RCIN
seen during the interim analysis, perhaps completing enrollment of
all 160 patients would have allowed the study to reach power,
giving it more merit.
The larger question here is how one defines nephropathy in this
setting, a controversial topic surrounding each of these studies.
Which end point is more reflective of deteriorating renal function:
changes in SCr, changes in creatinine clearance, or should a clinical
correlate be added to this definition such as a corresponding
decrease in urine output or need for hemodialysis? It may be
helpful if the RAPPID investigators provided more information
regarding patients who developed RCIN. A comparison of the
characteristics (SCr, radiocontrast volumes administered, clinical
consequences of RCIN, and length of stay) of patients developing
RCIN to those who did not may be helpful for readers when
interpreting the clinical significance of the data given the ques-
tionable statistical merit of the investigators’ findings.
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REPLY
DiDomenico and Eyrich question the definition of radiocontrast-
induced nephropathy (RCIN) and whether contrast nephropathy
occurred in the RAPPID study. The definition of RCIN employed
(a rise in serum creatinine 25%) is a widely accepted one and has
been used extensively (1–4). Furthermore, the clinical importance
of this definition has been demonstrated by the attendant increase
in in-hospital mortality when coronary intervention is associated
with this degree of renal impairment (1). The other commonly
used definition is a 0.5-mg/dl increase in serum creatinine post-
contrast exposure (5–9). Using this definition, the incidence of
RCIN in both control and n-acetylcysteine (NAC)-treated groups
of our study remains unchanged (Fig. 1).
Other suggested end points are unlikely to provide a more
appropriate reflection of deteriorating renal function. The inci-
dence of RCIN requiring renal replacement therapy, although of
considerable importance, is low following intra-arterial contrast
(7.7 cases per 1,000) and thus would require the study of many
thousands of patients (1). Change in urine output would be a
difficult end point to analyze, being dependent on standardization
of fluid intake. In addition, RCIN is frequently nonoliguric (10).
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